Quantcast
Last updated on April 20, 2014 at 14:04 EDT

Latest Hepatitis C/co-infection with HIV Stories

2011-10-03 06:15:00

HOERSHOLM, Denmark, and SAN DIEGO, Oct. 3, 2011 /PRNewswire/ -- Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA and mRNA-targeted therapies, today announced the Company will report new clinical data results from the miravirsen Phase 2a proof-of-concept study to treat patients infected with the Hepatitis C virus (HCV) in a late-breaking oral presentation session at the American Association for the Study of Liver Diseases...

2011-09-26 08:02:00

WATERTOWN, Mass., Sept. 26, 2011 /PRNewswire/ -- Enanta Pharmaceuticals, Inc. announced today that its lead development candidate from its NS5A hepatitis C virus (HCV) inhibitor program, EDP-239, has been recognized on Windhover's list of the "Top 10 Most Interesting Infectious Disease Projects to Watch." EDP-239 was chosen by independent experts at Windhover Information and Herndon Company. NS5A, a clinically-validated target, is a non-structural viral protein that is essential to viral...

2011-09-20 07:37:00

SANTA CRUZ, Calif., Sept. 20, 2011 /PRNewswire/ -- SomaGenics, Inc., a biotechnology company specializing in RNA-based technologies, presented exciting data on the efficacy of RNA interference (RNAi) therapeutics against Hepatitis C virus (HCV) based on the company's sshRNA platform. SomaGenics, along with its collaborators at Tekmira Pharmaceuticals and Roche, presented the results in a poster entitled "Synthetic Short shRNAs are Potent Inhibitors of Hepatitis C Virus in HCV-Infected...

2011-09-19 05:25:41

(Ivanhoe Newswire)--- According to the CDC, Hepatitis C is the most common chronic blood borne infection in the United States affecting more than 3.2 million people.  But, a new drug has been found to significantly increase the cure rates for those infected. Hepatitis C virus (HCV) is a disease that can cause severe liver damage, joint pain and even damage to the nervous system and brain. HCV genotype 1 is the most common form of the virus and also the most difficult to treat. ...

2011-09-15 12:18:57

Response-guided treatment with drug telaprevir can be shortened to 6 months for many, says research published in New England Journal of Medicine Treatment with a telaprevir-based combination regimen for hepatitis C — heretofore a chronic, destructive and difficult to manage disease — effectively can be shortened to six months in about two-thirds of patients, finds a new study published Thursday in the New England Journal of Medicine. Telaprevir, a drug approved for use...

2011-09-15 11:35:54

University of Cincinnati research published in the Sept. 14, 2011, advance online edition of the New England Journal of Medicine shows that patients with hepatitis C who took a combination medication–a telaprevir-based regimen that is commonly used to treat the illness–for 24 weeks were cured. Usually, the treatment is administered for 48 weeks, and these results show that extended treatment is unnecessary, possibly changing the standard of care for hepatitis C patients....

2011-09-15 11:34:05

A new multinational study finds that a 24-week treatment course for hepatitis C that adds telaprevir to peginterferon alfa and ribavirin is just as effective as a 48-week regimen for many patients. This is good news for up to 4 million people in the U.S. who suffer from this chronic liver disease, many of whom will undergo treatment for hepatitis C, said Michael W. Fried, MD, professor of medicine at the University of North Carolina at Chapel Hill, director of the UNC Liver Center and a...

2011-09-14 05:29:43

(Ivanhoe Newswire) — Genotyping hepatitis C patients significantly improves doctors´ ability to predict whether or not patients will respond to antiviral treatment. The results of the study suggest that an interaction between IL28B, HLA-C and KIRs genes provides a mechanism for hepatitis C viral control and highlight new insights into how the drug combination of pegylated interferon alpha and ribavirin clears hepatitis C virus infections, findings that may lead to improved...

2011-09-13 05:45:00

PRINCETON, N.J., Sept. 13, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today that screening has begun in a Phase 2b, international study of PSI-7977 and PSI-938, two nucleotide analog polymerase inhibitors for the treatment of chronic hepatitis C (HCV). The QUANTUM trial will evaluate interferon-free regimens of PSI-7977 400mg QD and PSI-938 300mg QD with and without ribavirin over 12 or 24 weeks in patients with HCV who have not been treated previously. The trial will...

2011-09-06 05:45:00

PRINCETON, N.J., Sept. 6, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS), announced today sustained virologic response (SVR) results from its phase 2b PROTON study with PSI-7977 400 mg dosed once daily in combination with peginterferon alfa 2a and ribavirin (Peg-IFN/RBV) in subjects with hepatitis C virus (HCV) genotype 1 who have not been treated previously. 43 out of 44 (98%) evaluable subjects achieved an SVR12, defined as HCV RNA below the limit of detection (<15 IU/mL) 12...


Latest Hepatitis C/co-infection with HIV Reference Libraries

11_9e88d15808b8ecc3fcbbdfcf4ae75786
2011-01-20 19:23:30

Hepatitis C virus (HCV) is an enveloped, positive-sense single-stranded RNA virus of the family Flaviviridae. It consists of a core of genetic material surrounded by an icosahedra protective shell of protein. The genome consists of a single open reading frame that is 9600 nucleotide bases long. HCV replication takes several steps. It primarily replicates in the hepatocytes of the liver. It can also reproduce in peripheral blood mononuclear cells. There is a wide variety of genotypes and...

More Articles (1 articles) »